Nebion
NEBION, now acquired by Immunai, offers the GENEVESTIGATOR platform, an advanced tool for transcriptome data analysis and genomic research. The company specializes in precise curation and structuring of large-scale biological data, including hundreds of thousands of samples and millions of cells, unified under a clinical ontology. Their platform supports researchers in academia and industry to make discoveries in pharmatech and drug development, leveraging AI and expert curation to enhance data quality and usability.
Nebion
NEBION, now acquired by Immunai, offers the GENEVESTIGATOR platform, an advanced tool for transcriptome data analysis and genomic research. The company specializes in precise curation and structuring of large-scale biological data, including hundreds of thousands of samples and millions of cells, unified under a clinical ontology. Their platform supports researchers in academia and industry to make discoveries in pharmatech and drug development, leveraging AI and expert curation to enhance data quality and usability.
TL;DR
What they do: Curated transcriptome/genomics data platform (GENEVESTIGATOR) and analytics for research and drug discovery
Headquarters: Zurich, Switzerland
Status: Acquired by Immunai (July 2021)
Founded: 2008
Company Overview
Problem Domain
Biological data curation and transcriptome/genomics analytics for research and drug development
Founded
2008
Industry
Bioinformatics / Genomics
Funding Track Record
10000.00
Last recorded funding date in provided evidence; company later acquired by Immunai in July 2021.
Investor Signal
“Acquired by Immunai (July 2021); prior investor listed as VentureKick”